Compared side by side
CJC-1295 no DAC vs sermorelin: how they differ
The short answer
Both are GHRH analogues that give short, pulse-like GH release: sermorelin is the unmodified first 29 amino acids of GHRH, with a half-life of about 11–12 minutes, and CJC-1295 no DAC (also sold as Mod GRF 1-29) is a modified form of the same chain whose half-life in people hasn’t been measured. Sermorelin is taken once a day before bed, CJC-1295 no DAC 2–3 times a day, usually with ipamorelin. Sermorelin was FDA-approved until its maker discontinued it in 2008; the no-DAC form has no published human studies.
Side by side
| Compared | CJC-1295 no DAC | Sermorelin |
|---|---|---|
| Category | Growth hormone | Growth hormone |
| Also known as | Modified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC | GHRH 1-29, GRF 1-29 |
| What it is | The shorter-acting version of CJC-1295, meant to give sharp, pulse-like GH release. | A synthetic copy of the first 29 amino acids of your natural growth hormone releasing hormone: it prompts your pituitary to release its own GH, keeping the body's feedback loops in play. |
| How it works | GHRH analogue without the DAC modification. Its half-life in people hasn't been measured (native GHRH lasts minutes), and the short action gives pulse-like GH release. Usually stacked with Ipamorelin to mimic natural GH secretion patterns. | Synthetic analogue of endogenous GHRH. Stimulates the pituitary to produce and secrete GH naturally. Considered a more physiological approach to GH optimization compared to exogenous GH. |
| Commonly reported | A flush or head rush within minutes of injecting, deeper sleep and vivid dreams early on, and mild water retention over the weeks. The no-DAC form itself has no published human studies. | Deeper sleep and vivid dreams in the first weeks, with gentle, slow-building effects, milder than CJC/ipamorelin. It was FDA-approved as a diagnostic test (1990) and to treat GH deficiency in children (1997) until the maker discontinued it in 2008, not for safety reasons. |
| Studied range | Research range: 100–200 mcg. Studied in research — not a recommendation. | Research range: 200–500 mcg, starting dose 200 mcg. Studied in research — not a recommendation. |
| How often | 2–3x daily | Daily, before bed |
| Half-life | ~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes) | ~11–12 min (US Geref label, after IV or SubQ) |
| Route | SubQ injection | SubQ injection |
| Typical run | 8–12 weeks typical. Usually stacked with Ipamorelin; cycle both together. | 3–6 months common; considered a more physiological approach so longer cycles are used. |
| Evidence | Moderate: animal studies + some human data | Established: clinical trials or FDA-approved use exists |
| Common side effects | Water retention, headache, flushing, injection site pain | Headache, flushing, dizziness, nausea, injection site reaction, water retention |
- Category
- CJC-1295 no DACGrowth hormone
- SermorelinGrowth hormone
- Also known as
- CJC-1295 no DACModified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC
- SermorelinGHRH 1-29, GRF 1-29
- What it is
- CJC-1295 no DACThe shorter-acting version of CJC-1295, meant to give sharp, pulse-like GH release.
- SermorelinA synthetic copy of the first 29 amino acids of your natural growth hormone releasing hormone: it prompts your pituitary to release its own GH, keeping the body's feedback loops in play.
- How it works
- CJC-1295 no DACGHRH analogue without the DAC modification. Its half-life in people hasn't been measured (native GHRH lasts minutes), and the short action gives pulse-like GH release. Usually stacked with Ipamorelin to mimic natural GH secretion patterns.
- SermorelinSynthetic analogue of endogenous GHRH. Stimulates the pituitary to produce and secrete GH naturally. Considered a more physiological approach to GH optimization compared to exogenous GH.
- Commonly reported
- CJC-1295 no DACA flush or head rush within minutes of injecting, deeper sleep and vivid dreams early on, and mild water retention over the weeks. The no-DAC form itself has no published human studies.
- SermorelinDeeper sleep and vivid dreams in the first weeks, with gentle, slow-building effects, milder than CJC/ipamorelin. It was FDA-approved as a diagnostic test (1990) and to treat GH deficiency in children (1997) until the maker discontinued it in 2008, not for safety reasons.
- Studied range
- CJC-1295 no DACResearch range: 100–200 mcg. Studied in research — not a recommendation.
- SermorelinResearch range: 200–500 mcg, starting dose 200 mcg. Studied in research — not a recommendation.
- How often
- CJC-1295 no DAC2–3x daily
- SermorelinDaily, before bed
- Half-life
- CJC-1295 no DAC~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes)
- Sermorelin~11–12 min (US Geref label, after IV or SubQ)
- Route
- CJC-1295 no DACSubQ injection
- SermorelinSubQ injection
- Typical run
- CJC-1295 no DAC8–12 weeks typical. Usually stacked with Ipamorelin; cycle both together.
- Sermorelin3–6 months common; considered a more physiological approach so longer cycles are used.
- Evidence
- CJC-1295 no DACModerate: animal studies + some human data
- SermorelinEstablished: clinical trials or FDA-approved use exists
- Common side effects
- CJC-1295 no DACWater retention, headache, flushing, injection site pain
- SermorelinHeadache, flushing, dizziness, nausea, injection site reaction, water retention
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
CJC-1295 no DAC
- Day 1–14 Sleep usually moves first
- Day 14–28 Recovery is quicker, skin looks better
- Day 28–56 Body composition starts shifting
- Day 56–84 Cycle endpoint
Sermorelin
- Day 1–14 Sleep is the first signal
- Day 14–42 Recovery and skin are responding
- Day 42–180 The long game is paying off
Together or one or the other
CJC-1295 no DAC and sermorelin are a common stack: CJC-1295 no DAC lists sermorelin among its common stacks.
Questions people ask
How long do CJC-1295 no DAC and sermorelin last?
The half-life of CJC-1295 no DAC is ~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes). The half-life of sermorelin is ~11–12 min (US Geref label, after IV or SubQ).
How often are CJC-1295 no DAC and sermorelin taken?
CJC-1295 no DAC: 2–3x daily. Route: SubQ injection. Sermorelin: daily, before bed. Route: SubQ injection.
How are CJC-1295 no DAC and sermorelin dosed in research?
The research range for CJC-1295 no DAC is 100–200 mcg. The research range for sermorelin is 200–500 mcg, with a 200 mcg starting dose. Studied in research — not a recommendation.
What are the common side effects of CJC-1295 no DAC and sermorelin?
For CJC-1295 no DAC, the library lists: water retention, headache, flushing, injection site pain. For sermorelin: headache, flushing, dizziness, nausea, injection site reaction, water retention.
Are CJC-1295 no DAC and sermorelin taken together?
CJC-1295 no DAC and sermorelin are a common stack: CJC-1295 no DAC lists sermorelin among its common stacks.